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C~ut~e~d~-~akoh disease is a slow, infectious, progressiive ~e~ol~~ic~~ disorder which results in human 
dementia. Synaptic membrane from various brain regions of guinea pigs infected with Creutzfeldt-knob 
disease show increased guanyi nucfeotide- or ~-hydroxy~~ptamine-rn~d~at~ ac ivation of adeny~a~e cyeiase. 
This increased enzyme activity appears due, primarity, to facilitated “coupling’ between the GTP-binding 
protein which stimulates adenyiate cyclase (GN,) and the catalytic moiety of that enzyme rather than in- 
creased sensitivity to Shydroxytryptamine. It is possible that this phenomenon is due to direct effects of 
the Creutzfeldt-Jakob infectious agent, or a pathological product resulting from that agent, upon synaptic 
membrane adenylate cyclase. 
GTP-binding protein Receptor-effector coupling 
Creutzfeldt-Jakob disease fc.ID) is a slow, infec- 
tious, progressive neurological disorder which 
results in human dementia, and may provide a 
paradigm for more common progressive human 
dementias such as Alzheimer’s disease. CJD is 
characterized by spongy or membranous changes 
in affected neuropil, particularly in synaptic 
regions [l]. Human autopsy material can be used 
to transmit CJD to rodents [2] and the infectivity 
is closely associated with a specific, synaptic 
membrane-~s~iated protein {3,4]. In order to 
study the possibifity that synaptic membrane ac- 
cumulation of CJD infectious agent, or agent 
elicited protein, causes clinical and pathological 
manifestations of CJD, the functional capacity of 
the neuronal membrane enzyme, adenylate 
cyclase, was examined. 
No&: Various authors have referred to these proteins as 
N (nucleotide binding protein) and G (GTP binding pro- 
tein), Here, we refer to these proteins as GN, or GNi - 
GN referring to guanine nucfeotide 
Oncogene product Dementia Signal transduction 
A variety of hormones or neurotransmitters 
mediate the activity of adenylate cyclase, however, 
in neuronal membranes this enzyme can be 
stimulated or inhibited directly by hydrolysis- 
resistant guanine nucleotides or F- and these ac- 
tions are expressed through separate guanine 
nucleotide-binding proteins: GN, (stimulation) and 
GNi (inhibition). The coupling of adenylate cyclase 
refers ta the interaction between (or among) 
neurotransmitter eceptor, GN, or GNi and the 
adenylate cyclase catalytic moiety. We have 
demonstrated previously that neuronal adenylate 
cyclase coupling might be augmented by 
treatments which alter cytoskeletal or membrane 
composition f5,6] and by chronic antidepressant 
treatment [7]. Thus, we undertook to investigate 
the possibility that the membrane changes 
associated with Creutzfeldt-Jakob infection might 
also effect changes in neuronal adenylate cyclase 
coupling. Further, recent investigations in rodents 
infected with scrapie (a spongiform encephalopa- 
thy similar to CJD) have detected iminished brain 
5-hydroxytryptamine (S-IT) leveb. In these 
studies, some of the behavioral aspects of scrapie 
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infection were ascribed to 5HT supersensitivity 
[8,9]. Pursuant to those studies, we chose addi- 
tionally to examine SHT-activated adenylate 
cyclase in brains of normal and CJD-infected 
guinea pigs. 
2. MATERIALS AND METHODS 
2.1. Animals 
We utilized a serially passaged guinea pig model 
of CJD [lo]. Synaptosome-enriched fractions were 
prepared as described [3] from animals showing 
typical clinical signs of disease (approx. 20 weeks 
after i.c. inoculation of young adult guinea pigs). 
Material from several serial passages was studied 
(i.e. passages 14-18), and all studies included (i) 
parietal cerebral cortex, (ii) hippocampus, and (iii) 
basal ganglia. Regions were rapidly dissected, 
synaptosomal fractions prepared, and aliquots of 
prepared membranes tored in liquid nitrogen until 
assay. Spongy changes are especially apparent in 
this CJD passaged material in cerebral cortex and 
basal ganglia [2]. Controls included normal young 
adult as well as older (Zyear-old) guinea pigs of 
the same strain, and synaptic membrane-enriched 
fractions were derived identically to those from in- 
fected animals. 
2.2. Adenylate cyclase assays 
Membranes were suspended in 20 mM Hepes 
(pH 7.4) with 5 mM MgC12, 1 mM DTT and 
0.3 mM PMSF and assayed in duplicate for 
adenylate cyclase as described [5]. Briefly, 2Opg 
membrane protein was preincubated with 5HT (in 
0.02% ascorbate) and/or other agents (as in- 
dicated) at 30°C for 20 min. Following this, ATP 
(5OOpM) was added (final incubation volume 
100,ul) and the reaction mixtures incubated at 
30°C for 10 min. Reactions were stopped by boil- 
ing (3 min) and the CAMP produced assayed by 
protein binding. Some experiments were per- 
formed similarly except that the assay was by the 
method of Salomon [26], and triplicate rather than 
duplicate determinations were made. These assays 
were stopped by the addition of 1% SDS rather 
than by boiling. 
3. RESULTS 
In all experiments (figs 1,2) there was a clear in- 
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Fig. 1. Adenylate cyclase activity in infected and control 
guinea pig basal ganglia membranes at indicated SHT 
concentrations. Guinea pigs were inoculated with a 10% 
homogenate of CJD passage brain [lo] and killed at late 
clinical stages of the disease. Histological confirmation 
of the disease was made in parallel cage-mates displaying 
similar symptomology. Fresh brain (control,---; or 
CJD-infected,-) synaptosome-enriched fractions 
from each region were prepared and assayed as 
described, in the presence of the indicated 5HT 
concentration plus 5 ,uM Gpp(NH)p. Values expressed 
are means of duplicate determinations for one of three 
similar experiments. 
crease in adenylate cyclase activity in membranes 
from CJD-infected animals. In membranes from 
CJD-infected animals, the magnitude of the 5HT 
response was enhanced (fig.1) without any ap- 
parent change in the 5HT sensitivity. Adenylate 
cyclase activation by 5HT in control membranes 
was somewhat less sensitive but otherwise com- 
parable to that reported in [1 11. Hippocampal 
membranes from infected animals showed a pat- 
tern of increased SHT-activated adenylate cyclase 
similar to that observed in the basal ganglia. 
Although the results in fig.1 indicate some in- 
creased 5HT responsiveness, they cannot be ex- 
plained on the basis of increased 5HT sensitivity 
due to the large increase in overall adenylate 
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cyclase activity inmembranes from CJD-infected 
animals. Therefore, other aspects of adenygate 
cycfase activation were examined. Basal adenylate 
cyclase activity was indistinguishable between 
rn~rnbra~~s prepared from infected animals and 
controls (fig.& lanes A). Adenyiate cyclase activity 
in the same preparations was also measured in the 
presence of MnS04. Mn2+ activates the catalytic 
moiety of adenylate cyclase, and under these assay 
conditions, is thought to reflect the activity of the 
enzyme which is independent of GN, [5,12f. If 
membranes were pathologically destroyed in CJD, 
one would expect to sea Iess adenyiate eyetase 
specific activity under these ~o~dit~o~s a com- 
pared to controls. fn both brain regions, the 
M~*~~stimu~ated catalytic moiety activity of 
adenyiate cycfase in CJD groups was comparable 
(fig2, lanes B). We then studied the GN,- 
dependent activation of adenylate cyclase by using 
NaP or the hydroIysis-resistant GTP analog, 
Gp~(NH)p. In the presence of 5 x foe6 M 
Gp~(N~)p (fig.2, Ianes C) both basal ganglia and 
hippo~ampus membranes howed an activation of 
adenylate cyclase that was s~g~ifi~a~~Iy greater 
than the eontrofs, At a submaximal ~~~~~~tration 
of ~pp(N~)p (10V7 M), adenylate cyclase ac- 
tivities in membranes from infected animals were 
85% (basal gan~ia) and 40% ~~p~o~~rnp~s) 
greater than controls in the illustrated experiment. 
The mean and standard deviation for S ex- 
periments indicated an increase in GppNHp- 
activated adenylate cyclase of 66 f 17% (mean it 
SD) in CJD-infected basal ganglia and 52 f 22% 
in CJD~i~~f~~t~d hippo~ampus compared to con- 
trols. Zn each experiment NaF also elicited in- 
creased adenylate cyclase activity in basal ganglia 
and hip~~~rn~us in CJ~-infected animals {e.g. 
lanes D, fig.2). Combined data for ah ex~~~~rnent~ 
showed an increase in N~-st~m~~ated a ~~yla~e 
cycfase of 100 + 20% (basal ganglia) and $6 zt 
16% (hipp~am~us) in membranes from CJD- 
infected animals as compared to controls. 
Unlike basal ganglia and hippocampus, cerebral 
cortex membranes from CJD-infected aaima!s 
showed a slight decrease in GppNHp~stim~l~t~d 
adenylate cyclase. The cerebral cortex shows mark- 
ed vacu~ii~~tio~ at end stages of CJD, and it is 
possible that these pathoiogi~al changes preclude 
detection of efevated adenylate cyclase in this 
EgiOXL 
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4. DISCUSSION 
It is clear from the above studies that the integri- 
ty of the adenylate cyclase system of membranes 
from basal ganglia and hippocampus remains in- 
tact in this disease, despite extensive pathological 
changes at the synaptic level [2,10]. Pathological 
changes in neurons secondary to CJD infection, 
and not necessarily entailing a direct or specific ef- 
fect on neuronal membranes, could lead to the in- 
creased adenylate cyclase activation obtained 
above. In this context, several mechanisms may be 
considered. For example, disruption of neuronal 
cytoskeletal integrity, consistent with the focal 
clearing observed in synaptic processes of CJD- 
infected animals [12,14,15], may increase 
adenylate cyclase activity. It has been 
demonstrated previously by that activation of 
neuronal adenylate cyclase through GN, is en- 
hanced as a consequence of treatment with 
microtubule-disrupting drugs or agents which in- 
crease membrane fluidity [5,6,15]. Furthermore, 
selective damage of SHT-containing neurons can 
lead to SHT-stimulated adenylate cyclase supersen- 
sitivity in SHT-responsive neurons. 5HT supersen- 
sitivity (due to reduced 5HT levels) has been in- 
voked to explain some of the behavioral changes 
observed in scrapie-infected rodents [9, lo], and an 
increased response to 5HT may be present with 
respect to adenylate cyclase in the CJD-infected 
animals in these studies. Increased 5HT response 
observed in basal ganglia, which may be consistent 
with some depletion of 5HT at presynaptic ter- 
minals, is dependent upon low (5 x IO-“) GppNHp 
concentrations in the adenylate cyclase assay. 
However, increased response to 5HT does not 
alone explain increased adenylate cyclase activa- 
tion in membranes from CJD-infected animals by 
NaF or GppHNp. Reserpine treatment [I 11, 
chronic electroconvulsive shock and chronic treat- 
ment with tricyclic antidepressants [7] can also 
enhance brain adenylate cyclase. The reserpine ef- 
fect is similar to that observed in CJD where 
elevated 5HT responsiveness was found at essen- 
tially all concentrations tested and is compatible 
with enhanced coupling of the GN, protein to 
adenylate cyclase, rather than (or in addition to) a 
specific receptor-mediated enhancement. In sum- 
mary, this work shows an increased interaction 
(coupling) of GN, as the predominant consistent 
finding in CJD membranes from basal ganglia and 
hippocampus. Additionally, 5HT supersensitivity 
in basal ganglia may occur secondary to 
pathological depletion of 5HT terminals in that 
region. 
Both CJD and scrapie are related infectious 
agents, and similar specific sialoglycoproteins have 
been identified in both diseases [4,16,18]; these 
proteins share common antigenic epitopes [4,15] 
and are found in subcellular fractions that are 
highly infectious. These proteins, as well as infec- 
tivity and unique fibrils, cosediment with, and are 
tightly bound to, synaptosome-enriched or synap- 
tic membrane fractions [3,4]. It is possible that in- 
sertion of CJD-specific proteins into neuronal 
membranes directly alters the interaction of GN, 
with the adenylate cyclase catalytic moiety. 
Another possibilty is that a CJD-elicited mem- 
brane protein mimics GN, in the activation of 
adenylate cyclase. Although at present we have no 
evidence favoring a direct membrane effect over 
one secondary to other neuronal pathology (e.g. 
cytoskeletal changes), it is of interest that recent 
experiments on ras proteins, have indicated that 
oncogene products (p21-related membrane pro- 
teins) can directly bind guanine nucleotides and 
display GTPase activity [20]. There is some se- 
quence homology between ras proteins and 
adenylate cyclase GN proteins 120,211 and rus 
membrane proteins might substitute for GN, in the 
activation of adenylate cyclase [22] associated with 
transformed growth potentials (this is a matter of 
some controversy [23]). Although CJD and scrapie 
are degenerative diseases, there is some evidence 
that exposure to these agents can also result in 
altered growth potentials and cell transformation 
[24,25]. Perhaps a similar protein and similar 
phenomena account for the observed increase in 
GN, activated adenylate cyclase in CJD 
membranes. 
Further investigation of (i) adenylate cyclase 
response patterns during the long incubation 
period of CJD (e.g. at early and preclinical stages 
of infection), (ii) the nature of CJD specific pro- 
tein(s) interactions with membrane components 
(i.e. the ability of these proteins to bind guanine 
nucleotides), and (iii) membrane alterations in 
CJD-transformed cells should help to clarify the 
exact target of these ‘unconventional’ infectious 
agents and their role in the genesis of 
encephalopathy. 
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